Fran Gregory, PharmD, MBA, vice president of Emerging Therapies at Cardinal Health, discussed the role biosimilars are playing in the pharmaceutical market as well as in patient access.
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health, discusses the role the new wave of biosimilars will have on rebate practices for both pharmacy benefit managers (PBMs) and payers.
Gregory also discussed the differences between specialty pharmacy distribution and physician’s office distribution, and the benefits of each for patients.
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health, discusses what's to come as a result of a "second wave" of biosimilars hitting the market.
Fran Gregory, PharmD, MBA, vice president of Emerging Therapies at Cardinal Health, discussed the biosimilars landscape and where biosimilars fall in the process of pharmacy and medical benefit adoption.